Induction of protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 in mice by shiga-like toxin-liposome conjugate. 1998

T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
Department of Bacterial and Blood Products, National Institute of Infectious Diseases, Tokyo, Japan.

We have previously reported that purified Shiga-like toxins (SLT), SLT-I and SLT-II coupled with liposomes induced a substantial amount of anti-SLT-I and anti-SLT-II IgG antibody production, respectively, in mice. The levels of anti-SLT antibody in the sera of SLT-liposome-immune mice correlated well with the protection against subsequent challenge with SLT. In this study, mice were immunized intraperitoneally with the mixture of SLT-I-liposome and SLT-II-liposome and protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 was evaluated. All of the mice that received immunization with the mixture of SLT-I-liposome and SLT-II-liposome were protected against subsequent intravenous challenge with 10 LD50 of either SLT-I or SLT-II. Eight weeks after primary immunization, mice were inoculated intragastrically with 10(9) CFU of E. coli O157:H7 strain 96-60. All SLT-liposome-immune mice tested survived without any apparent symptom while control mice died within 5 days. In addition, as shown by other antigen-liposome conjugates, SLT-liposome induced undetectable anti-SLT IgE antibody production while they induced substantial amounts of anti-SLT IgG antibodies. These results suggest that SLT-liposome conjugate may serve as a candidate vaccine that induces protection against cytotoxin-producing E. coli infection.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009059 Mouth Diseases Diseases involving the MOUTH. Disease, Mouth,Diseases, Mouth,Mouth Disease
D003603 Cytotoxins Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from CYTOSTATIC AGENTS in degree of effect. Some of them are used as CYTOTOXIC ANTIBIOTICS. The mechanism of action of many of these are as ALKYLATING AGENTS or MITOSIS MODULATORS. Cytolysins,Cytotoxic Agent,Cytotoxic Agents,Cytotoxin,Agent, Cytotoxic
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001427 Bacterial Toxins Toxic substances formed in or elaborated by bacteria; they are usually proteins with high molecular weight and antigenicity; some are used as antibiotics and some to skin test for the presence of or susceptibility to certain diseases. Bacterial Toxin,Toxins, Bacterial,Toxin, Bacterial
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
June 1999, World journal of gastroenterology,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
January 1999, Emerging infectious diseases,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
April 2004, Infection and immunity,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
March 2000, Infection and immunity,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
March 1997, Letters in applied microbiology,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
July 2011, Journal of food protection,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
August 1999, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
February 2008, Clinical and vaccine immunology : CVI,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
March 2011, Journal of clinical microbiology,
T Fukuda, and T Kimiya, and M Takahashi, and Y Arakawa, and Y Ami, and Y Suzaki, and S Naito, and A Horino, and N Nagata, and S Satoh, and F Gondaira, and J Sugiyama, and Y Nakano, and M Mori, and S Nishinohara, and K Komuro, and T Uchida
January 2012, Revista Argentina de microbiologia,
Copied contents to your clipboard!